| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T200 |
0-18 |
Sentence |
denotes |
Oleoylethanolamide |
| T201 |
19-182 |
Sentence |
denotes |
Oleoylethanolamide (OEA), synthesized in the gastrointestinal tract, is a bioactive lipid mediator derived from the omega-9 monounsaturated fatty acid, oleic acid. |
| T202 |
183-374 |
Sentence |
denotes |
Based on previous evidences, OEA showed anti-inflammatory activities, a role in modulation of immune response, anti-oxidant effects and stimulation of lipolysis and fatty acid oxidation [72]. |
| T203 |
375-582 |
Sentence |
denotes |
In this context OEA is considered an endocannabinoid-like lipid, which interacts with the peroxisome proliferator-activated receptor-alpha (PPAR-α) and intervenes during the anti-inflammatory processes [73]. |
| T204 |
583-801 |
Sentence |
denotes |
Scientific researchers recently showed that endocannabinoid system is involved in the management of infectious agents such as viruses, bacteria, and some protozoa, also reducing inflammation and pain in the lungs [74]. |
| T205 |
802-1113 |
Sentence |
denotes |
In view of the fact that SARS-CoV-2 infection leads to increase the pro-inflammatory cytokines, including IL-6 and IL-1β in COVID-19 patients via binding to the TLRs, an important components of the innate immune system, it is assumed that OEA inhibits this pathway through its anti-inflammatory properties [75]. |
| T206 |
1114-1331 |
Sentence |
denotes |
OEA binds with high affinity to PPAR-α receptors and increases the expression level of anti-inflammatory cytokine such as IL-10, then initiates a cascade of events, which can attenuate the inflammatory responses [73]. |
| T207 |
1332-1489 |
Sentence |
denotes |
Furthermore, OEA attenuates the inflammatory responses modulating the expression of TLR-4, and interfering with the ERK1/2/AP-1/STAT3 signaling cascade [73]. |
| T208 |
1490-1637 |
Sentence |
denotes |
OEA may modulate cross-talk between PPAR-α and TLRs and regulates the inflammatory responses with beneficial synergistic effect against SARS-CoV-2. |
| T209 |
1638-1973 |
Sentence |
denotes |
Nowadays, discovering therapeutic options from currently available agents appears to be essential for the treatment and prophylaxis of this pandemic, especially in obese patients with comorbidities [76] and this bioactive lipid mediator can be considered as a novel potential pharmacological alternative for the management of COVID-19. |
